Saturday, 31 October 2026European Markets

ESTORIL SOL N Stock Went Up By Over 10% So Far On Thursday

Loading stream...

(VIANEWS) - Shares of ESTORIL SOL N (PSI: ESON.LS) rose by a staggering 10.34% to €8.00 at 14:25 EST on Thursday, following the last session's upward trend. PSI is falling 0.41% to €6,043.30, after three sequential sessions in a row of losses. This seems, up until now, a somewhat negative trend exchanging session today.

About ESTORIL SOL N

Estoril Sol, SGPS, S.A., together with its subsidiaries, engages in the gaming activities and real estate businesses. It owns gaming casinos, including casino do Estoril, Casino Lisboa, and Casino da Póvoa. The company is also involved in the online casino games and gambling business, as well as online sports betting activities. In addition, it owns a plot of land in Monte Estoril. Further, the company engages in tourism business. The company was incorporated in 1958 and is headquartered in Estoril, Portugal. Estoril Sol, SGPS, S.A. is a subsidiary of Finansol - Sociedade de Controlo, SGPS, S.A.

Earnings Per Share

As for profitability, ESTORIL SOL N has a trailing twelve months EPS of €2.86.

PE Ratio

ESTORIL SOL N has a trailing twelve months price to earnings ratio of 2.8. Meaning, the purchaser of the share is investing €2.8 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESTORIL SOL N's stock is considered to be oversold (<=20).

More news about ESTORIL SOL N (ESON.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com